SGLT-2 Inhibitors in Heart Failure *ACPE-Accredited*

The podcast centers on SGLT-2 inhibitors, examining their evolution from diabetes medications to first-line treatments for various types of heart failure, even in patients without diabetes. It highlights cardiovascular safety studies required by the FDA, noting the varying outcomes among drugs within the same class. The discussion covers landmark trials like CANVAS, EMPA-REG outcomes, and DECLARE-TIMI 58, which revealed cardiovascular benefits and prompted further investigation into heart failure applications. The hosts also explore the mechanisms behind SGLT-2 inhibitors' benefits in heart failure, including osmotic diuresis, vascular effects, and improved myocardial metabolism. They compare different SGLT-2 inhibitors, such as empagliflozin and dapagliflozin, and also touch on the dual SGLT-1 and SGLT-2 inhibitor, sotagliflozin, and its clinical trial results.